New drug-radiation combo targets deadly brain tumors in early trial
NCT ID NCT06824662
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This early-phase trial tests whether adding the drug quisinostat to standard radiation therapy can help control glioblastoma, a fast-growing brain cancer. About 30 adults with newly diagnosed or recurrent glioblastoma will receive the drug before and during radiation. The goal is to see if the drug reaches the tumor and improves how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, WHO GRADE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
Conditions
Explore the condition pages connected to this study.